TiumBio티움바이오

TiumBio's revenue is growing but operating losses remain very large relative to sales, and the share price is down sharply over the past year.

TiumBio is a loss-making biopharma developer whose lead candidate is Tosposertib (TU2218), an anticancer immunotherapy. In the trailing twelve months to H1 2026 it booked about ₩15.0B of revenue against an operating loss of about ₩16.1B, and it has borrowings of ₩14.9B against cash of ₩3.7B. The shares closed at ₩4,080 on 2026-10-23, roughly 70% below the 52-week high of ₩13,700.

What stands out

• Revenue rose to ₩12.3B in 2025 from ₩6.8B in 2024, up 80.9%, but operating losses were still about ₩16.1B, an operating margin of -131.4%.
• TTM free cash flow is about -₩15.7B, and liabilities are 179.9% of equity, so the company depends on funding to cover its burn.
• The P/B of 3.4 and P/S of 8.2 are given, but P/E and EV/EBITDA are not meaningful because earnings are negative; no fair value estimate is in the data.
• Recent filings include a 5%+ holding report, a share sale in another company, stock purchase option grants and a conversion price adjustment, all dated September to October 2026.
• Foreign ownership fell to 3.4% from 4.7% over 60 days, and 20-day foreign flows were net selling of about ₩0.1B.

What to watch

• The next quarterly or annual results and whether operating losses narrow relative to revenue.
• Clinical or regulatory updates on Tosposertib (TU2218); the data does not include a trial timeline.
• Further financing, dilution from options or convertible adjustments, and debt repayment against the ₩14.9B of borrowings.